Sales Ended

Denali Therapeutics Info Session

Event Information

Share this event

Date and Time

Location

Location

Stanley Hall, Room 106, UC Berkeley

View Map

Event description

Description

Denali Therapeutics

Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development. Founded by a team of former Genentech executives, Denali has quickly grown to become one of the leading companies in field, focusing on diseases such as Alzheimer’s disease, Parkinson’s disease, ALS, and others. Come hear about the work going on at one of the Bay Area’s most innovative companies!

Denali covers a wide range of job disciplines. To learn more, go to their website at http://www.denalitherapeutics.com/

Agenda:

6:00 pm - 7:00 pm: Denali Seminar

7:00 pm - 8:00 pm: Networking happy hour


Speakers:

JOE LEWCOCK

HEAD OF BIOLOGY DISCOVERY

Joe Lewcock serves as the Head of Biology Discovery at Denali. Prior to joining Denali Joe spent 9 years at Genentech, where he helped to build the neuroscience research team and portfolio. In his role as Director of the Department of Neuroscience, he was responsible for generating the disease area strategy and management of the neuroscience portfolio, which included both large and small molecule programs. Joe also served as a project team leader, where he led a small molecule program from target discovery to IND filing. His lab focused on identification of new therapeutic drug targets for Amyotrophic Lateral Sclerosis (ALS), Parkinson’s, and Alzheimer’s Disease. Joe received his B.S. from University of California, San Diego, a Ph.D. from Johns Hopkins University School of Medicine, and completed a postdoctoral fellowship at the Salk Institute.


ZACH SWEENEY

HEAD OF THERAPEUTIC DISCOVERY

Zach Sweeney leads the Therapeutic Discovery group at Denali. Previously, he was a Director of Global Discovery Chemistry and Head of Analytical Chemistry at Novartis Emeryville. Zach also worked as a scientist at Genentech and Roche. His project teams have contributed to the identification of clinical candidates for the treatment of Parkinson's disease, inflammatory disorders, and infectious disease. Zach's teams have also authored over 40 patent applications and 30 scientific articles. He graduated with a degree in chemistry from Stanford University, received a Ph.D. from the University of California, Berkeley, and completed a postdoctoral fellowship at Harvard University.

If you have any questions, please contact PIEP at ucb.piep@gmail.com or visit our website at: http://piep.berkeley.edu/

Check out our LinkedIn page! https://www.linkedin.com/groups/3890299

By registering, you will be automatically added to the PIEP mailing list. You can unsubscribe at any time.

Share with friends

Date and Time

Location

Stanley Hall, Room 106, UC Berkeley

View Map

Save This Event

Event Saved